Clinical Trial Update: Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction [Phase 1]

View source ↗

Summary

Phase 1 trial of vorinostat in adults with metastatic or unresectable solid tumors or lymphoma and liver dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous B-cell Non-hodgkin Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Grade Iii Lymphomatoid Granulomatosis
• Intraocular Lymphoma
• Nasal Type Extranodal Nk T-cell Lymphoma
• Nodal Marginal Zone B-cell Lymphoma

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Status: COMPLETED